Evidence map›Paper›PMID 34221859›Full record

ReviewActa pharmaceutica Sinica. B2021

The role of ALDH2 in tumorigenesis and tumor progression: Targeting ALDH2 as a potential cancer treatment.

Hong Zhang, Liwu Fu

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 136 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. The role of KPNA3 in multiple myeloma: implications for targeting nuclear import.Apoptosis : an international journal on programmed cell death · 2026
    Article
  8. Review
  9. [Construction of a prognosis forecasting model for breast cancer based on lipid metabolism-related genes and functional verification ofZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Journal of thoracic disease · 2025
    Article
  18. Article
  19. Carcinogenicity of vinyl acetate: evidence from multiple data streams.Environmental health : a global access science source · 2025
    Review
  20. Article

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hong ZhangState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Liwu FuState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A major mitochondrial enzyme for protecting cells from acetaldehyde toxicity is aldehyde dehydrogenase 2 (ALDH2). The correlation between ALDH2 dysfunction and tumorigenesis/growth/metastasis has been widely reported. Either low or high ALDH2 expression contributes to tumor progression and varies among different tumor types. Furthermore, the ALDH2∗2 polymorphism (rs671) is the most common single nucleotide polymorphism (SNP) in Asia. Epidemiological studies associate ALDH2∗2 with tumorigenesis and progression. This study summarizes the essential functions and potential ALDH2 mechanisms in the occurrence, progression, and treatment of tumors in various types of cancer. Our study indicates that ALDH2 is a potential therapeutic target for cancer therapy.

Indexed as

4-HNE, 4-hydroxy-2-nonenalAcetaldehydeALD, alcoholic liver diseaseALDH2ALDH2, aldehyde dehydrogenase 2AMPK, AMP-activated protein kinaseBCa, bladder cancerCancerCancer therapyccRCC, clear-cell renal cell carcinomasCOUP-TF, chicken ovalbumin upstream promoter-transcription factorCRC, colorectal cancerCSCs, cancer stem cellsDFS, disease-free survivalEC, esophageal cancerFA, Fanconi anemiaFANCD2, Fanconi anemia proteinGCA, gastric cancerHCC, hepatocellular carcinomaHDACs, histone deacetylasesHNC, head and neck cancerHNF-4, hepatocyte nuclear factor 4HR, homologous recombinationLCSCs, liver cancer stem cellsMDA, malondialdehydeMDR, multi-drug resistanceMetastasisMN, micronucleiNAD, nicotinamide adenine dinucleotideNCEs, normochromic erythrocytesNeG, 1,N2-etheno-dGuoNER, nucleotide excision repair pathwayNF-κB, nuclear factor-κBNHEJ, non-homologous end-joiningNRF2, nuclear factor erythroid 2 (NF-E2)-related factor 2NRRE, nuclear receptor response elementNSCLC, non-small-cell lungOPC, oropharyngeal cancerOS, overall survivalOvCa, ovarian cancerPBMC, peripheral blood mononuclear cellPC, pancreatic cancerPdG, N2-propano-2′-deoxyguanosinePolymorphismProgressionREV1, Y-family DNA polymeraseSCC, squamous cell carcinomaTGF-β, transforming growth factor βTumorigenesisVHL, von Hippel-LindauεPKC, epsilon protein kinase C

Identifiers

PMID34221859
PMCPMC8245805
OpenAlexW3128252230

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.